BACKGROUND Non-selective and selective beta-blockers have been shown to improve outcomes in chronic heart failure (CHF). Recent data suggests the non-selective beta-blockers have a more favourable effect on outcomes than beta(1)-selective agents. We sought to examine the differential effects of non-selective versus selective beta-blockade on myocardial substrate utilization in patients with CHF...

A four month old infant with isolated left ventricular non-compaction was treated with carvedilol. Haemodynamic studies and various types of imaging—including echocardiography, radiographic angiography, magnetic resonance imaging, and single photon emission computed tomography with Tl, I-â-methyliodophenylpentadecanoic acid (BMIPP), and I-metaiodobenzylguanidine (MIBG)— were performed before an...

Cardiovascular disease is the leading cause of death worldwide. Within the treatment armamentarium, beta-blockers have demonstrated efficacy across the spectrum of cardiovascular disease--from modification of a risk factor (ie, hypertension) to treatment after an acute event (ie, myocardial infarction). Recently, the use of beta-blockers as a first-line therapy in hypertension has been called i...

A simple, sensitive and reliable method is described for simultaneous quantification of Carvedilol and its metabolite 4-Hydroxyphenyl Carvedilol in human plasma by using High-throughput liquid Chromatography–tandem mass spectrometric method. The method was carried out by on-line coupling of extraction with Cyclone P (50 mm × 0.5 mm 50 μm) HTLC(High-throughput liquid Chromatography) column by in...

OBJECTIVE To determine baseline predictors of tolerance to the alpha/beta blocker carvedilol in everyday clinical practice. DESIGN Retrospective analysis of tolerance to carvedilol in patients with chronic heart failure. Tolerance was defined as currently on carvedilol or on it at the time of death or heart transplantation. To meet the criteria for tolerance, carvedilol had to be prescribed a...

Carvedilol is a cardiovascular drug of multifaceted therapeutic potential, with beta-blocker and vasodilatative activity. These actions confer to the above mentioned betablocker some beneficial properties on several processes involving cardiovascular system. Carvedilol provides haemodynamic, antiischemic, antiproliferative and antiarrhytmic benefits, for its antioxidant neurohumoral and electro...

BACKGROUND Carvedilol reduces mortality and hospitalization in adults with congestive heart failure. Limited information is available about its use in children. METHODS We reviewed the medical records of 24 children with dilated cardiomyopathy and left ventricular ejection fraction of <or=40%, who were treated with carvedilol as adjunct therapy to angiotensin-converting enzyme inhibitors, dig...

AIM Previous studies have shown that carvedilol has a neuroprotective effect in animal models of brain ischemia and brain oxidative damage in vitro. This study was perfomed to investigate the effect of carvedilol on the secondary damage in experimental spinal cord injury (SCI). MATERIAL AND METHODS Twenty-four Wistar albino rats were divided into three groups. Group 1 underwent laminectomy al...

A sensitive, selective and simple method for the simultaneous determination of carvedilol enantiomers in aqueous solution has been developed using stir bar sorptive extraction (SBSE) followed by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. This method is based on the reaction of carvedilol enantiomers with (-)-menthyl chloroformate (MCF) after extraction by the...

The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine g...